D. E. Shaw & Co., Inc. Gritstone Bio, Inc. Transaction History

D. E. Shaw & Co., Inc.

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$1.77 - $4.34 $18,183 - $44,584	-10,273 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$4.03 - $12.19 $1.36 Million - $4.12 Million	-337,638 Reduced 97.05%	10,273 $42,000
Q4 2021 Feb 14, 2022	SELL	$8.76 - $13.71 $8.51 Million - $13.3 Million	-971,882 Reduced 73.64%	347,911 $4.48 Million
Q3 2021 Nov 15, 2021	BUY	$6.41 - $13.54 $417,117 - $881,088	65,073 Added 5.19%	1,319,793 $14.3 Million
Q2 2021 Aug 16, 2021	BUY	$8.13 - $10.2 $5.81 Million - $7.29 Million	714,922 Added 132.44%	1,254,720 $11.5 Million
Q1 2021 May 17, 2021	BUY	$4.07 - $27.11 $1.36 Million - $9.04 Million	333,436 Added 161.58%	539,798 $5.09 Million
Q4 2020 Feb 16, 2021	BUY	$2.57 - $4.22 $69,891 - $114,762	27,195 Added 15.18%	206,362 $813,000
Q3 2020 Nov 16, 2020	BUY	$2.63 - $8.09 $471,209 - $1.45 Million	179,167 New	179,167 $475,000
Q1 2019 May 15, 2019	SELL	$9.97 - $18.96 $100,996 - $192,064	-10,130 Closed	0 $0
Q4 2018 Feb 14, 2019	BUY	$11.61 - $31.1 $117,609 - $315,043	10,130 New	10,130 $157,000

35.4M

395K

132K

Ticker GRTS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 73,006,896
Market Cap $2.19M
Description
Gritstone bio, Inc., a clinical-stage biotechnology company, engages in developing immunotherapies against multiple cancer types and infectious diseases. Its lead product candidate is GRANITE, a neoantigen-based immunotherapy for the treatment of solid tumors, including metastatic non-small cell lung cancer, as well as gastroesophageal, bladder ...

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.